The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective

被引:54
|
作者
Garbaccio, Robert M. [1 ]
Parmee, Emma R. [1 ]
机构
[1] Merck Res Labs, Global Chem, Mailstop 14-2,740 Sumneytown Pike, West Point, PA 19486 USA
来源
CELL CHEMICAL BIOLOGY | 2016年 / 23卷 / 01期
关键词
SMALL-MOLECULE INHIBITORS; PEPTIDASE-IV INHIBITOR; RECEPTOR; TARGET; ANTAGONIST; POTENT; CELLS; AKT; REPLICATION; MK-0657;
D O I
10.1016/j.chembiol.2015.11.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemical probes represent an important component of both academic and pharmaceutical drug discovery research. As a complement to prior reviews that have defined this scientific field, we aim to provide an industry perspective on the value of having high-quality chemical probes throughout the course of preclinical research. By studying examples from the internal Merck pipeline, we recognize that these probes require significant collaborative investment to realize their potential impact in clarifying the tractability and translation of a given therapeutic target. This perspective concludes with recommendations for chemical probe discovery aimed toward maximizing their potential to identify targets that result in the successful delivery of novel therapeutics.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [1] The impact of chemoinformatics on drug discovery in the pharmaceutical industry
    Martinez-Mayorga, Karina
    Madariaga-Mazon, Abraham
    Medina-Franco, Jose L.
    Maggiora, Gerald
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (03) : 293 - 306
  • [2] The impact of natural products on drug discovery in the pharmaceutical industry
    David, B.
    PLANTA MEDICA, 2007, 73 (09) : 802 - 802
  • [3] Translational Medicine for Stroke Drug Discovery The Pharmaceutical Industry Perspective
    Feuerstein, Giora Z.
    Chavez, Juan
    STROKE, 2009, 40 (03) : S121 - S125
  • [4] Biological reactive intermediates in drug discovery and development - A perspective from the pharmaceutical industry
    Baillie, TA
    Kassahun, K
    BIOLOGICAL REACTIVE INTERMEDIATES VI: CHEMICAL AND BIOLOGICAL MECHANISMS IN SUSCEPTIBILITY TO AND PREVENTION OF ENVIRONMENTAL DISEASES, 2001, 500 : 45 - 51
  • [5] PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING IN DRUG DISCOVERY AND DEVELOPMENT: A PHARMACEUTICAL INDUSTRY PERSPECTIVE
    Chen, Yuan
    Jones, Hannah
    Gibson, Christopher R.
    Heimbach, Tycho
    Parrott, Neil
    Peters, Sheila
    Snoeys, Jan
    Upreti, Vijay
    Zheng, Ming
    Hall, Stephen David
    DRUG METABOLISM REVIEWS, 2015, 47 : 105 - 106
  • [6] Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development: A Pharmaceutical Industry Perspective
    Jones, H. M.
    Chen, Y.
    Gibson, C.
    Heimbach, T.
    Parrott, N.
    Peters, S. A.
    Snoeys, J.
    Upreti, V. V.
    Zheng, M.
    Hall, S. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (03) : 247 - 262
  • [7] DRUG DISCOVERY AND DEVELOPMENT IN THE PHARMACEUTICAL-INDUSTRY
    SCHACTER, LP
    ANDERSON, C
    CANETTA, RM
    KELLEY, S
    NICAISE, C
    ONETTO, N
    ROZENCWEIG, M
    SMALDONE, L
    WINOGRAD, B
    SEMINARS IN ONCOLOGY, 1992, 19 (06) : 613 - 621
  • [8] A PHARMACEUTICAL-INDUSTRY PERSPECTIVE ON DRUG LABELING
    ROBINSON, DS
    PSYCHOPHARMACOLOGY BULLETIN, 1994, 30 (01) : 23 - 25
  • [9] Continuing evolution of the drug discovery process in the pharmaceutical industry
    Ratti, E
    Trist, D
    PURE AND APPLIED CHEMISTRY, 2001, 73 (01) : 67 - 75
  • [10] The continuing evolution of the drug discovery process in the pharmaceutical industry
    Ratti, E
    Trist, D
    FARMACO, 2001, 56 (1-2): : 13 - 19